Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 19/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390792 | 0.86 | GPR119 (0.69) | GPR119CYP2C9KCNH2NPC1RAB9A | |
| SCHEMBL390682 | 0.84 | GPR119 (0.79) | GPR119CYP2C9KCNH2 | |
| SCHEMBL388204 | 0.84 | GPR119 (0.79) | GPR119CYP2C9KCNH2 | |
| SCHEMBL388652 | 0.82 | GPR119 (0.76) | GPR119CYP2C9KCNH2NPC1 | |
| SCHEMBL386623 | 0.82 | GPR119 (0.76) | GPR119CYP2C9KCNH2 | |
| SCHEMBL388759 | 0.82 | GPR119 (1.00) | GPR119CYP2C9KCNH2 | |
| SCHEMBL391165 | 0.81 | GPR119 (0.71) | GPR119CYP2C9KCNH2NPC1ALDH1A1 | |
| SCHEMBL27747879 | 0.79 | GPR119 (0.82) | GPR119CYP2C9KCNH2 | |
| SCHEMBL389668 | 0.78 | GPR119 (0.74) | GPR119CYP2C9KCNH2 | |
| SCHEMBL386467 | 0.78 | GPR119 (0.74) | GPR119CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |